UNCY
Unicycive Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$215.74M
P/E Ratio
—
EPS
$-2.25
Beta
1.77
52W High
$11.00
52W Low
$3.71
50-Day MA
$7.26
200-Day MA
$5.88
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
3.44
PEG Ratio
—
About Unicycive Therapeutics Inc
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for kidney diseases, particularly targeting hyperphosphatemia. The firm's proprietary drug candidates aim to effectively manage phosphorus levels, critical in the treatment of renal disorders. With a strong emphasis on research and development and a strategic approach to partnerships, Unicycive is poised to make significant contributions in the field of nephrology. As the company advances its clinical trials, it represents a compelling investment opportunity for institutional investors looking for transformative solutions in healthcare.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-29.93M |
| Operating Margin | 0.00% |
| Return on Equity | -163.10% |
| Return on Assets | -40.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.49 |
| Price-to-Book | 5.72 |
| Price-to-Sales (TTM) | 23.75 |
| EV/Revenue | 16.63 |
| EV/EBITDA | -1.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $26.70M |
| Float | $24.28M |
| % Insiders | 2.36% |
| % Institutions | 37.65% |
Historical Volatility
HV 10-Day
53.32%
HV 20-Day
47.98%
HV 30-Day
51.24%
HV 60-Day
54.33%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($40.99 target)
2
Strong Buy7
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026